Log in to your Inderes Free account to see all free content on this page.

Isofol Medical

0.72 SEK

-0.96 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-0.96 %

+1.27 %

+22.97 %

-1.23 %

+4.12 %

-31.72 %

+34.54 %

-91.72 %

-94.66 %

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is great.

Market cap

230.75M SEK

Turnover

181.67K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

25.8.

2026

Interim report Q2'26

12.11.

2026

Interim report Q3'26

12.2.

2027

Annual report '26

All

Webcasts

Press releases

3rd party

ShowingAll content types

Regulatory press release5/19/2026, 2:45 PM

Bulletin from annual general meeting in Isofol Medical AB (publ) held on 19 May, 2026

Press release5/19/2026, 11:14 AM

Redeye: Isofol Medical (Q1 Review): Tailwind despite slower recruitment

Third party research5/19/2026, 7:38 AM

Isofol Medical: Taking action on recruitment - ABG

* Solid cost control * Slower-than-expected patient recruitment * Negative share price reaction expected Solid cost control Net income came in fairly in line with expectations at SEK -15m (vs. ABGSCe at SEX -14m and SEK -13m in Q4'25), with CF from operating...

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release5/19/2026, 6:00 AM

Isofol Medical AB (publ) publishes interim report, January – March 2026

Regulatory press release4/30/2026, 6:00 AM

New number of shares and votes in Isofol

Regulatory press release4/15/2026, 2:00 PM

Notice to attend the Annual General Meeting held on May 19, 2026 in Isofol Medical AB (publ)

Press release4/15/2026, 7:10 AM

Isofol optimizes the design of its phase Ib/II study following new regulatory approval

Regulatory press release4/10/2026, 6:00 AM

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2025

Regulatory press release3/31/2026, 3:00 PM

Isofol receives gross proceeds of 18.9 MSEK in connection with the exercise of warrants and guarantee commitments for warrants of series TO1, and resolves on a directed share issue

Regulatory press release3/18/2026, 12:50 PM

Isofol secures license rights for arfolitixorin in autism

Regulatory press release3/13/2026, 5:40 PM

The subscription price for warrants of series TO1 in Isofol has been set at SEK 0.48 and the exercise period commences on 16 March 2026

Regulatory press release3/11/2026, 2:30 PM

Isofol receives top guarantee commitment and letters of intent corresponding to 42 percent of upcoming warrant exercise

Regulatory press release3/9/2026, 10:00 AM

Isofol’s Nomination Committee proposes election of Christian Haglund as new Board Director

Press release3/3/2026, 7:30 AM

Isofol presents at investor meetings in March

Third party research2/25/2026, 6:22 AM

Isofol Medical: From first lessons to second execution - ABG

* Strong early efficacy signal * Solid cost management * Fair value range of SEK 0.1-10.5/share Strong early efficacy signal Isofol today announced that all six currently evaluable RAS-mutated metastatic colorectal cancer patients in Part 1 of its Phase...

Regulatory press release2/24/2026, 8:32 AM

Isofol provides update on the ongoing phase Ib/II clinical study of arfolitixorin

Press release2/19/2026, 8:36 AM

Redeye: Isofol Medical (Q4 Review): Translational year ahead

Regulatory press release2/18/2026, 6:30 AM

Isofol Medical AB (publ) publishes year-end report, January – December 2025

Third party research1/15/2026, 12:46 PM

Isofol Medical: Learn from the first, deliver on the second - ABG

* Targeting a huge unmet medical need * Revised best-in-class potential * Fair value range of SEK 0.1-10.5/share Huge unmet medical needIsofol is developing arfolitixorin, a next-generation active folate designed to enhance standard chemotherapy built...

Press release1/9/2026, 6:30 AM

Isofol participates in the ASCO GI congress

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.